Clinical Research Directory
Browse clinical research sites, groups, and studies.
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Sponsor: Alexion Pharmaceuticals, Inc.
Summary
Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).
Official title: Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies (C5ITs)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2019-12-02
Completion Date
2029-10-01
Last Updated
2026-02-18
Healthy Volunteers
No
Conditions
Locations (51)
Clinical Trial Site
Birmingham, Alabama, United States
Clinical Trial Site
Scottsdale, Arizona, United States
Clinical Trial Site
Fresno, California, United States
Clinical Trial Site
Orange, California, United States
Clinical Trial Site
Rancho Mirage, California, United States
Clinical Trial Site
Sylmar, California, United States
Clinical Trial Site
Colorado Springs, Colorado, United States
Clinical Trial Site
Fort Collins, Colorado, United States
Clinical Trial Site
New Haven, Connecticut, United States
Clinical Trial Site
Washington D.C., District of Columbia, United States
Clinical Trial Site
Clearwater, Florida, United States
Clincal Trial Site
Gainesville, Florida, United States
Clinical Trial Site
Jacksonville, Florida, United States
Clinical Trial Site
Tampa, Florida, United States
Clinical Trial Site
Augusta, Georgia, United States
Clinical Trial Site
Iowa City, Iowa, United States
Clinical Trial Site
Lexington, Kentucky, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Lansing, Michigan, United States
Clinical Trial Site
Columbia, Missouri, United States
Clinical Trial Site
New Hyde Park, New York, United States
Clinical Trial Site
Chapel Hill, North Carolina, United States
Clinical Trial Site
Charlotte, North Carolina, United States
Clinical Trial Site
Durham, North Carolina, United States
Clinical Trial Site
Dayton, Ohio, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Clinical Trial Site
Chattanooga, Tennessee, United States
Clinical Trial Site
Knoxville, Tennessee, United States
Clinical Trial Site
Dallas, Texas, United States
Clinical Trial Site
Houston, Texas, United States
Clinical Trial Site
Burlington, Vermont, United States
Clinical Trial Site
Milwaukee, Wisconsin, United States
Clinical Trial Site
Vienna, Austria
Clinical Trial Site
Brampton, Ontario, Canada
Clinical Trial Site
London, Ontario, Canada
Clinical Trial Site
Montreal, Quebec, Canada
Clinical Trial Site
Chengdu, Sichuan, China
Clinical Trial Site
Beijing, China
Clinical Trial Site
Changchun, China
Clinical Trial Site
Chengdu, China
Clinical Trial Site
Guangzhou, China
Clinical Trial Site
Jinan, China
Clinical Trial Site
Nanchang, China
Clinical Trial Site
Qingdao, China
Clinical Trial Site
Shijiazhuang, China
Clinical Trial Site
Hanover, Hannover, Germany
Clinical Trial Site
Milan, Italy
Clinical Trial Site
Naples, Italy
Clinical Trial Site
Abhā, Saudi Arabia
Clinical Trial Site
Jeddah, Saudi Arabia
Clinical Trial Site
Riyadh, Saudi Arabia